title: Remission induction with carboplatin-epirubicin-prednimustine followed by consolidation radiotherapy in advanced ovarian cancer.
abstract: Adjuvant chemoradiotherapy was administered to 26 patients with stage Ic-IV ovarian cancer after radical cytoreductive surgery. All patients received six cycles of carboplatin, epirubicin, and prednimustine and had no clinical evidence of disease after completion of chemotherapy. They received whole-abdominal radiation and radiation to the retroperitoneal lymph nodes. This protocol was discontinued for five (23%) patients because of myelosuppression, progressive disease, or withdrawal. One patient had a small bowel obstruction due to intraperitoneal adhesions. The survival of ten stage-III ovarian cancer patients, who received chemoradiotherapy and were evaluable for assessment of treatment efficacy, was retrospectively compared with the survival of 11 stage-III patients who received chemotherapy only. At 36 months, a slight advantage of the chemoradiotherapy versus the chemotherapy-only group was observed (p = 0.11). These preliminary results suggest that adjuvant chemoradiotherapy may prolong the "no evidence of disease" interval of radically operated ovarian cancer patients. Toxicity is acceptable when second-look surgery is avoided and when subsequent radiotherapy is limited to patients with no evidence of disease.
authors.affiliation: Department of Obstetrics and Gynaecology, University of Graz, Austria.
authors.forename: E
authors.initials: E
authors.lastname: Petru
authors.forename: H
authors.initials: H
authors.lastname: Pickel
authors.forename: M
authors.initials: M
authors.lastname: Heydarfadai
authors.forename: M
authors.initials: M
authors.lastname: Lahousen
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015182:Lymphatic Irradiation; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D011238:Prednimustine / Q000008:administration & dosage; D012074:Remission Induction
chemical_list: D015251:Epirubicin; D011238:Prednimustine; D016190:Carboplatin